Key facts
- This page summarizes Patrick Machado's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jun 2024, 18:20.
Patrick Machado - 06 Jun 2024 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)
- Reporting relationship
- Director
- Issuer ticker
- RCUS
- Reported as of
- 06 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2024, 18:20:31 UTC
- Prior SEC filing
- 05 Jun 2024
- Next SEC filing
- 11 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carolyn Tang, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Machado filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 07 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RCUS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,400
- Change %
- +50%
- Price
- $0.000000
- Shares after
- 25,300
- Date
- 06 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RCUS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +24,000
- Change %
- Price
- $0.000000
- Shares after
- 24,000
- Date
- 06 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,000
- Exercise price
- $15.90
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Footnote F2
The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.